



Annual report March 2024

Annual educational meeting held on October 5th, 2023

Mallinckrodt Sponsored Session 10:00 - 10:40 To improve overall survival in acute GvHD by applying ECP Dr. Melhem M. Solh, Northside Hospital, Atlanta, Georgia

Sanofi Sponsored Session 10:40 - 11:20: The dual role of ROCK2 inhibitors and ECP in treating GvHD Dr Corey Cutler, Dana-Farber Cancer Institute, Boston, Massachusetts 11:20 - 11:40

11:40 - 13:00 Nurse-led Symposium: Vascular access, Vascular Issues + Audit Ms Anne McDermott,
13:00 - 14:00 Lunch and Poster viewing

14:00 - 14:45 UKPS Business meeting

14:45 - 15:30 E-CLAD Trial: Update and progress Professor Andrew Fisher, Newcastle University

15:30 - 15:45 Afternoon coffee break 15:45 - 16:15

E-CLAD: Immunology update Mr Steven Bolton, Newcastle University 16:15 - 16:45

Investigating Extracellular Vesicles in ECP Response in Patients with GvHD Dr Rachel Crossland,
Newcastle University 16:45 - 17:00 Summary & Close

Research Grants:

‘Mechanisms of action of ECP therapy for GvHD, focusing on the role of EV-derived microRNAs’, which aims to further understanding the molecular mechanisms of ECP action, including EV microRNAs, as well as identify biomarkers for using ECP as first line or pre-emptive GvHD therapy.’

Dr Rachel Crossland Newcastle University



**Statement of accounts for the UKPS for Jan31 2023 to Jan 2024 presented to
Board**

Charity registration number: 1178321

Jan 2023 Balance: £93,968

Educational events:

UKPS 2023: £4,120 (Friends House)

Research Grant Jan 2024 : New castle University £14,691.14

Mallinckrodt Ltd. : £20,000 (paid in as meeting support)

Current balance Sep 2019: £102,597.26

Dr Arun Alfred 1/3/24

Treasurer UKPS